Lilly's $1.9B Move into RNA Gene-Editing for Kidneys

Eli Lilly (LLY) entered into a $1.9 billion licensing deal with Ascidian Therapeutics to access RNA exon editing technology for treating rare inherited kidney diseases. This agreement broadens Lilly’s genetic medicine capabilities as the pharmaceutical company pursues innovative therapeutic solutions for conditions lacking adequate treatment alternatives ¹.

Key Takeaways

Lilly secures exclusive access to Ascidian’s RNA editing platform
Agreement valued at up to $1.9 billion with milestones and royalty payments
Targets genetically caused kidney diseases impacting millions of patients

Deal Structure and Technology

The arrangement includes an undisclosed initial payment from Lilly, followed by development, regulatory and commercial milestone payments, plus tiered royalties on eventual product sales ². The collaboration revolves around Ascidian’s RNA exon editing platform, which substitutes defective RNA segments to enable the production of functional proteins.

This methodology provides potential benefits compared to conventional gene therapy by circumventing permanent DNA modifications while utilizing delivery mechanisms other than viral vectors ³. Over 60 genetic disorders impact kidney function, with more than 3.5 million Americans experiencing severe hereditary kidney disease.

Market Context and Strategic Rationale

This transaction marks Lilly’s continued growth in genetic medicine following recent acquisitions such as the $1 billion Verve Therapeutics deal and collaborations with Seamless Therapeutics and MeiraGTx ⁴. Following the announcement, Lilly stock declined 1.67% to close at $1,064.15.

Existing therapeutic options for numerous inherited kidney disorders are often restricted to managing symptoms, dialysis or organ transplantation. RNA exon editing has the potential to tackle “the fundamental cause of the disease,” according to Robert Bell, Ascidian’s chief scientific officer ³.

Ascidian’s Platform and Pipeline

The Boston-headquartered Ascidian has established its platform as a lower-risk alternative to direct gene modification while preserving therapeutic efficacy ³. The company is currently conducting early human trials for a Stargardt disease therapy and has previously established a $1.8 billion research partnership with Roche targeting neurological conditions.

“Lilly is both a radar and a magnet in genetic medicines,” stated Daniel Rosan, Ascidian’s chief financial and business officer ³. The organizations have maintained ongoing discussions since before Ascidian’s 2022 establishment, with both parties recognizing that kidney-focused genetic therapies have reached “a point of tractability that probably wasn’t true five years ago.”

Industry Outlook

This collaboration demonstrates increasing pharmaceutical sector investment in genetic medicine technologies capable of treating multiple conditions. Lilly’s strategic expansion in this arena establishes the company’s competitive position in advanced therapeutics beyond its established diabetes and obesity drug leadership.

Neither company has revealed specific targets for their initial partnership, although the extensive genetic kidney disease market represents considerable unmet medical demand with significant commercial opportunities.

Not investment advice. For informational purposes only.